What's New in the Evolving Management of
Diabetes: Individualizing Therapy with
Novel Treatment Options
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 10, 2018 to January 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grant from
Boehringer Ingelheim and Lilly USA Alliance
The American Diabetes Association (ADA) estimates that more than
25.8 million people in the United States have diabetes and that 1 in
3 Americans born in 2017 will develop diabetes at some point of
their life. Approximately 90-95% of adults have type 2 Diabetes
Mellitus (T2DM) and the Centers for Disease Control (CDC) estimates
that uncontrolled type T2DM doubles a person’s risk for death, and
on average a loss of 10-15 years of life. The management of type
T2DM remains a major challenge as many patients continue to struggle
with achieving therapeutic goals, including control of A1C level,
blood pressure, cholesterol, and weight. The price tag associated
with treatment of type T2DM increases with disease severity, as more
dollars are spent managing the significant comorbidities associated
with advanced disease. Moreover, it is estimated that diabetes
patients, on average, have medical expenditures that are
approximately 2.3 times higher relative to the absence of diabetes.
Fortunately, recent advances in treatments have given healthcare
professionals the ability to shrink the clinical practice gap and
implement therapeutic strategies to effectively treat this disease.
Incorporating an individualized regimen for patients, to include
education, lifestyle change, mono and combination therapy of GLP-1
agonists, insulins and SGLT-2 inhibitors, will help overcome the
barriers associated with T2DM.
Upon Completion of this
activity, participants will be able to:
Summarize recent clinical data
regarding the role of newer antidiabetic therapies in reducing
macrovascular risk factors associated with T2DM, including
hypertension and heart failure
Understand the roles of newer GLP-1
agonists, insulins and SGLT-2 inhibitors in the type 2 diabetes
Examine recent clinical data related
to the combination of basal insulin and GLP-1 therapies and
their role in the type 2 diabetes treatment paradigm
||Carol H. Wysham, MD,
Clinical Professor of Medicine
University of Washington, Spokane
Rockwood Center for Diabetes and Endocrinology
acts as an advisor or consultant for Abbott,
AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Eli
Lilly, Janssen Pharmaceuticals, Novo Nordisk, and Sanofi.
She also serves as a speaker or a member of a speaker’s
bureau for AstraZeneca, Boehringer Ingelheim
Pharmaceuticals, Insulet Corporation, Eli Lilly, Janssen
Pharmaceuticals, Novo Nordisk, and Sanofi. Her
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
Boehringer Ingelheim and Lilly USA Alliance
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue